Suppr超能文献

双替格拉韦纳米胶束和阴离子普鲁兰阴道薄膜:HIV 的双重机制暴露前预防(PrEP)。

Bictegravir nanomicelles and anionic pullulan loaded vaginal film: Dual mechanistic pre-exposure prophylaxis (PrEP) for HIV.

机构信息

College of Pharmacy and Health Sciences, St. John's University, NY, USA.

Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL, USA.

出版信息

Int J Biol Macromol. 2022 Nov 30;221:416-425. doi: 10.1016/j.ijbiomac.2022.08.211. Epub 2022 Sep 6.

Abstract

Locally delivered pre-exposure prophylaxis (PrEP) has proven to be a promising strategy to combat Human immunodeficiency virus (HIV) transmission but several findings encountered toxicities or proved to be marginally effective in clinical settings. Therefore, innovative, multifunctional, and safer alternatives are being progressively investigated. Herein, we explored negatively charged carbohydrate, anionic pullulan (AP) as a rapidly soluble film-former and novel anti-HIV agent. Additionally, Bictegravir (BCT), an HIV integrase inhibitor was co-delivered in the form of nanomicelles for sustained antiviral activity. BCT-loaded PLGA-PEG polymeric nanomicelles (BN) were incorporated into PVA/pullulan-based film matrix comprising of 2 % w/v AP (BN-AP film). In cell-based assays, biocompatibility and TEER values for BN-AP films were similar to control while the commercial vaginal contraceptive film (VCF®) showed severe cytotoxicity and drastically reduced the tight junction integrity. Rapid disintegration of BN-AP film with >85 % drug release was observed in simulated vaginal and seminal fluid. Most importantly, AP and BN-AP film significantly inhibited HIV-1 replication with IC at as low as 91 μg/mL and 0.708 nM, respectively. Therefore, this study entails successful development of BN-AP film that functioned as an effective, biocompatible dual-acting PrEP formulation.

摘要

局部递药的暴露前预防(PrEP)已被证明是一种有前途的策略,可以对抗人类免疫缺陷病毒(HIV)的传播,但在临床环境中,一些发现遇到了毒性问题或效果不佳。因此,正在逐步探索创新的、多功能的和更安全的替代方案。在这里,我们研究了带负电荷的碳水化合物,阴离子普鲁兰(AP)作为一种快速可溶性成膜剂和新型抗 HIV 药物。此外,双替拉韦(BCT)作为 HIV 整合酶抑制剂,以纳米胶束的形式共同递送来实现持续的抗病毒活性。载有 BCT 的 PLGA-PEG 聚合物纳米胶束(BN)被掺入包含 2% w/v AP 的 PVA/普鲁兰基薄膜基质中(BN-AP 薄膜)。在细胞基础实验中,BN-AP 薄膜的生物相容性和 TEER 值与对照相似,而商业阴道避孕药膜(VCF®)则表现出严重的细胞毒性,并大大降低了紧密连接的完整性。在模拟阴道和精液中,BN-AP 薄膜迅速崩解,药物释放率超过 85%。最重要的是,AP 和 BN-AP 薄膜分别以低至 91μg/mL 和 0.708 nM 的 IC 显著抑制了 HIV-1 的复制。因此,本研究成功开发了 BN-AP 薄膜,它是一种有效的、生物相容的双重作用的 PrEP 制剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验